FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's

Voyager Therapeutics, Inc.

VY1706 targets intra- and extracellular tau; IND cleared by FDA on June 1, 2026.
Phase 1 open-label, dose-escalation trial expected to begin dosing in H2 2026.
Trial to enroll up to 18 early AD patients across 3 cohorts; highest dose 5 x 10^13 vg/kg.
Primary endpoint: safety/tolerability; secondary endpoints: CSF tau biomarkers and tau PET imaging.
Company plans to initiate multi-site study; VY1706 administered as one-time IV dose.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.